Insight into Hungarian HIV situation 9th Advanced HIV Course, EACS 09.2011, Aix en Provence Botond Lakatos, HU.

Slides:

Advertisements

Similar presentations

Single Pill HIV Regimens – Introducing the Quad Pedro Cahn, MD Jean-Pierre Routy, MD Calvin Cohen, MD.

Advertisements

Douglas T. Dieterich, Juergen K. Rockstroh, Kenneth E. Sherman, Nathalie Adda, Lisa Mahnke, Varun Garg, Shahin Gharakhanian, Scott McCallister, Vincente.

HIV/AIDS in Brazil at a glance 11th Advanced HIV Course 1 – 3 September 2013, Aix-en-Provence, France Ana Flor Hexel Cornely Clinical Hospital, Porto Alegre.

1 AIDS EPIDEMIC IN COTE DIVOIRE TCHOMIAN Clement ADJE Technical Advisor, for care and support EGPAF.

Management of ART in Albania : From the European Guidelines to the real practice. Arjan Harxhi MD, MSc, PhD University Hospital Center of Tirana Mother.

Solange Arazi Caillaud. MD Emiliano Bissio. MD María Ester Lázaro. MD.

HIV/AIDS situation in Serbia GORDANA J

HIV Situation in India Dr Sunil Gaikwad.

Eruptive Angiomas Maximilian C. Aichelburg 9th EACS Advanced HIV Course 7-9 September 2011 Aix-en-Provence France.

Ulcer on the upper arm Maximilian C. Aichelburg 9th EACS Advanced HIV Course 7-9 September 2011 Aix-en-Provence France.

EACS COURSE Aix-en-Provence Sep Ireland Dublin Capital City.

No Goals at Half-time: What Next for the Millennium Development Goals? Goal 6: Combating HIV/AIDS, malaria and other diseases John Porter.

Seafarers and HIV infection

Clinical Care: 2010 Institute of Medicine Committee on HIV Screening and Access to Care Michael Saag, MD, FIDSA University of Alabama, Birmingham Director,

UNAIDS World AIDS Day Report | 2011

ARV failure and resistance for the paediatrician

ARV overview and toxicity Dr Francois Venter Reproductive Health Research Unit University of the Witwatersrand.

Pre Test !!!!!!. How many classes of HIV meds are currently available?

Antiretroviral drugs in UMMC Presenter: TE CHIN YEW Preceptor: KHOO SU LIN.

The Medicines Patent Pool advancing innovation, expanding access, promoting public health Charles Clift Chair, Medicines Patent Pool

HIV Treatment and Intellectual Property Rights: The Experience of the Medicines Patent Pool Esteban Burrone Melbourne – International AIDS Conference July.

MONITORING SYSTEM FOR THE ANTIRETROVIRAL THERAPY IN BRAZIL: LESSONS LEARNED AND FUTURE DIRECTIONS Marco Vitória, MD Brazilian STD/AIDS Programme - MOH.

Fabio Mesquita, MD, PhD Director of the Brazilian Ministry of Health’s HIV/AIDS and Viral Hepatitis Department July 20th, 2014 Evidence.

ANTIRETROVIRAL THERAPY Dr. Samuel Mwaniki (BPharm., MSc TID, UoN) University of Nairobi ISO 9001: Certified

HIV Care 2010: The 3 rd Revolution in HIV treatment Chris Farnitano, MD Noon Conference February 11, 2010.

HIV Lifecycle and Mechanisms of Antiretroviral Therapy

The Future of HIV Treatment Melbourne – International AIDS Conference

DHS/HIV/PP HIV/AIDS 2007 Update David H. Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine Division of Infectious.

Presented by: Siti Rohaizah bt Othman. Arv DRUGS AVAILABLE IN UMMC Combivir (Lamivudine + Zidovudine) Stocrin (Efavirenz 600mg) Kaletra (Lopinavir 200mg.

ANTIRETROVIRAL RESISTANCE Jennifer Fulcher, MD, PhD.

Introduction to new drugs: I-Base training London - May 2007 Introduction to new drugs African Treatment Advocacy Training 31 May 2007 Simon Collins

HIV and AIDS Global: 40M HIV positive 25M AIDS deaths from ‘80 (60% sub-Saharan Africa) 80+% male Canada:63K HIV positive 16K AIDS deaths since 1980 (83%

HIV opportunistic infections and HIV treatment Sabrina Assoumou, MD Section of Infectious Diseases.

Footprint-based identification of viral entry inhibitors targeting HIVgp41 Mr. Holden 9/18/2012.

HIV Therapy Experience is the Best Teacher David K. Stein, M.D. Director, Adult HIV Research Activities Jacobi Medical Center Associate Professor of Clinical.

Aids Facts About Prevention. Disease Facts Found in tears, saliva,nervous system tissue, spinal fluid, and breast milk.

1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.

© IAS–USA Johnson VA et al. Top Antivir Med. 2011;19(4): Updates, user notes, and references available at Mutations in the.

The Medicines Patent Pool Ellen ‘t Hoen UNITAID Consultative Forum Geneva, 4-5 October 2011.

Medicines Patent Pool and Seychelles A primer For more information visit:

1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Why African Americans Must Understand and Participate in Clinical Trials and Vaccines Virginia A. Caine, M.D. Associate Professor of Medicine Division.

Ministry of Health Health Surveillance Secretariat NATIONAL STD/AIDS PROGRAMME.

AIDS ΘΕΡΑΠΕΙΑ Κατευθυντήριες Οδηγίες ΓΕΩΡΓΙΟΣ ΠΑΝΟΣ BSc(Biomed.Eng.), CEng, MIET, MD, PhD, DTM&H(Lon), FRCP Αν. Καθηγητής Παθολογίας & Λοιμωδών Νοσημάτων.

HIV: WHAT IS NEW? DR NYA EBAMA, M.D. LOWCOUNTRY INFECTIOUS DISEASES, PA CARETEAM PLUS, INC SEPTEMBER 18, 2015.

Antiretroviral targets in the viral life cycle Viral Replication and Drug targets.

MANAGEMENT OF HIV Involves both treatment of the virus and prevention of opportunistic infections. The aims of HIV treatment are : Reduce the viral load.

AN OVERVIEW OF PHARMACOVIGILANCE OF HIV/AIDS IN NIGERIA

© IAS–USA Johnson VA et al. Top Antivir Med. 2013;21(1):4-12. Updates, user notes, and references available at Mutations in the Reverse.

Phase 3 Treatment-Naïve and Treatment-Experienced

Effects of Switching ZDV-3TC to TDF-FTC or ABC-3TC SWAP

Antiretroviral Therapy (ART)

RAL + MVC + DRV/r + TDF-FTC

EFV versus ATV + RTV, both with ABC-3TC or TDF-FTC ACTG 5202

Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase.

Updated DHHS Adult and Adolescent HIV Treatment Guidelines: Conversation with Dr. Paul Sax Presentation prepared by: Paul Sax, MD and Brian Wood, MD.

ART 101 Successful HIV treatment usually consists of at least three drugs from two different “classes” of ARV drugs There are now six classes of ARV drugs:

HIV/AIDS By: Khatiga Shervani , Karla Molina, Tiffany Cordero, and Claribel Torres Ms. Green and Ms. Geshke Period 3.

Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses

Giới thiệu về điều trị ARV

Comparison of current lowest global price vs estimated generic price, for medicines for diseases with large international treatment programmes. Comparison.

Outwitting Evolution: Fighting Drug-Resistant TB, Malaria, and HIV

Phase 3 Treatment Naïve and Treatment Experienced HIV Coinfection

Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase.

Forecasting for ARVs medicines

F. Canducci, B. Barda, E. Ceresola, V. Spagnuolo, M. Sampaolo, E

Antiretroviral therapy and its complications

Figure 1. Rate of PDR in infants according to ARV exposure

Tertiary structures of HIV-1 protease and chemical formulas of HIV protease inhibitors. Tertiary structures of HIV-1 protease and chemical formulas of.

ANTIRETROVIRAL RESISTANCE IN CLINICAL PRACTICE

Presentation transcript:

Insight into Hungarian HIV situation 9th Advanced HIV Course, EACS , Aix en Provence Botond Lakatos, HU

epidemiology EPINFO HUN,2010; UNAIDS/WHO,2009 HIV Estimated prevalence: people (<0.1%) : 1100 person : 700 person AIDS : 573/ : 23/9 2010: 21/8 Late presenters: ~60% Female: 13% Children: 9 Regional distribution

care Single-center care About 1100 HIV infected people appeared 1000 are under frequent medical control 600 on HAART Care and drugs are provided by state ~85% of them are supressed VL 74% capable to work EPINFO HUN,2008(45), 2010(46)

National AIDS Committee AIDS Prevention Program treat Symptomatics Asymptomatics –CD4 > 350: CART tenofovir/emtricitabin, ABC/3TC, ZDV/3TC, tenofovir, ddI efavirenz, nevirapin, etravirin lopinavir, fosamprenavir, atazanavir, darunavir maraviroc raltegravir prevention/treatment

case 26 m, 2010, no attend doctor, MSM cough, haemoptoe, fever, pleurodynia CD4: 31/ μ l, c/ml CT: upper lobe cavitation BAL: encapsulated fungi elements Culture, latex: Cryptococcus neoformans (R to FLU) CSF: neg amphotericinB, itraconazol CART

Thank you and for EACS!